HUT70023A - Novel nitrogenous macrocyclic ligands and process for preparing them - Google Patents

Description

The present invention relates to novel nitrogen-containing cyclic ligands, H- ² -as-k-epaetate-phosphorus-complex 1 and

-r refers to complex-content-diagnostic-co-therapy-coo-judgments. The present invention relates to the preparation of j ligands. "For the production process ^x * £ e-»,

Diagnostic and therapeutic agents of the invention

The compositions are useful as agents for inducing chemical shifts in vivo in the fields of magnetic resonance imaging and X-ray radiology, and in the field of nuclear radiation therapy.

More particularly, the present invention relates to ligands of formula I wherein:

A 1, A 2, A 3 and A 4 are each independently of the formula (a) wherein m and n are each independently an integer from 1 to 5,

R 4 and R 5 are each independently hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, or polyhydroxyalkyl; a functional group which allows the attachment of the macrocycle of formula I to a macromolecule; straight or branched C 1-6 -alkoxy (C 1-6) -alkyl; straight or branched chain hydroxy (1-6C) alkoxy (1-6C) alkyl group or groups linear or branched polyhydroxy (1-6C) alkoxy (1-6C) alkyl groups ^R i with , aryl or mono- or polysubstituted aryl, wherein the substituents may be independently halogen, hydroxy, nitro or (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) polyhydroxyalkyl, C 6 -C 6 alkoxy or C 1 -C 6 -alkoxy (C 1 -C 6) -alkyl, aralkyl or mono- or polysubstituted aralkyl, wherein the substituents are independently halo, hydroxy, nitro or C 1-6 -alkyl; C 1-6 hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy, or C 1-6 alkoxy (C 1-6) alkyl, wherein in the aralkyl C 1-6 alkyl, straight or branched,

R _lo is R ₄ or R 5, hydroxy, C 1-6 alkoxy,

_R2 and R3 are each independently hydrogen,

Rg Rg Rg Rg Rg R] 3

I I II II

-CH-COOH, -CH-PO3H2, CH-COO-, -CH-PO ₃ ^- or -CH ₂ PO-group wherein

R 8 is hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl or straight or branched chain, C 1 -C 6 alkoxy (C 1 -C 6) alkyl, and

R 13 is a straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl or polyhydroxyalkyl, straight or branched C 1-6 alkoxy (1-6C) alkyl. C 6 -alkyl or straight or branched C 1 -C 6 -hydroxyalkoxy or polyhydroxyalkoxy-C 1 -C 6 -alkyl,

B is a group of formula N-W, wherein

W is a group of formula (Ia) wherein p and g are independently 0 to 6,

Rij and Rj2 independently of one another R _lo report if p is different from, and has the same meaning as R4 and R5, when p is 0, and

X is a group of formula (b) or (b1) wherein

_R6 and R7 together with the carbon to which they are attached, can optionally form a fused ring consisting of two, up to 12-membered heterocyclic ring, wherein 1-4 member heteroatom such as O, -N = and / or NR ₈ group, wherein

R 8 is hydrogen, straight or branched C 1 -C 6 alkyl, straight or branched C 1 -C 6 hydroxyalkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, or straight or branched; a branched C 1 -C 6 alkoxy group, a phosphorus atom or a sulfur atom, the heterocyclic ring being optionally substituted one or more times with the substituents being hydroxy-substituted, mercapto, straight or branched C 1 -C 6 alkyl, straight or branched, C 1-6 hydroxyalkyl, straight or branched, C 1-6 polyhydroxyalkyl, straight or branched C 1-6 alkoxy (C 1-6) alkyl, straight or branched, C 6 -C 6 hydroxyalkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 polyhydroxyalkoxy (C 1 -C 6) alkyl, or functional groups thereof eat, which allow coupling of the heterocyclic ring is a macromolecule with the proviso that when p and q is 0, Rg and _R7

_-CH2- or CH = CH Alta Rio or a radical of formula wherein

R _lo is as defined above; obsession

W is a group of formula (a2) wherein p, q, R 1, R ₂ , R ₃ , R 11, R 12 / Αχ, A ₂ , A ₃ and A ₄ are as defined above, and

Z is optionally a two-membered heterocyclic ring of up to 12 membered fused rings wherein 1-4 membered heteroatoms, such as oxygen, -N = and / or N-R ₈ , wherein R ₈ is as defined above for the heterocyclic ring. optionally mono- or polysubstituted, wherein the substituents are hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched, C 1-6 hydroxyalkyl, straight or branched, C 1-6 polyhydroxyalkyl, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxyalkoxy (C 1 -C 6) alkyl, linear or branched chain C 1 -C 6 polyhydroxyalkoxy (C 1 -C 6) alkyl or functional groups that allow the heterocyclic ring

Coupling macromolecule, from 0 to 5 jolontóoo integer with the proviso that at least two Rp, R ₂ and R ₃ represents one

Rg Rg Rg Rg

IIIi

-CH-COOH, -CH-PO3H2, CH-COO ^-, -CH-PO3- ^R 9 ^R 13 or -CH ₂ PO "radical,

R8 and R13 are as defined above;

where Αχ, R ₂ , ^R 4 ' ^r 5 * ^r 8' ^r 9 · ^R 10 * ^R 11 » ^R 2 θ ^Ξ RX ₃ mean different Αχ, R ₂ , R ₄ , R 5, R ₈ , R ₈ , Rxoz ^R 11 / ^r 2t and RX 3, when 1, m, n and q are other than O, or if several of the above groups are present, and salts of these compounds with inorganic or organic bases or basic amino acids.

Preferred are compounds of formula II which are a more narrow group of compounds of formula I wherein

R x, R ₂ , R 3 and W are as defined above, and ^R 1, R ₂ and R 13 are each independently the same as R ₄ or R ₅ above.

Especially preferred are compounds of formula (II), those wherein R x, R ₂ and R 3 is -CH ₂ -COOH.

Also preferred among these ligands are those compounds of formula III wherein R ₂ and R ₃ are hydrogen, methyl or ethyl, and W is as defined above.

Preferred values of X include thienyl, dihydrothienyl, tetrahydrothienyl, furyl, dihydrofuryl, tetrahydrofuryl, pyranyl, dihydropyranyl, tetrahydropyranyl, pyrrolyl, 2H-pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl, imidazolyl, pyrazolyl, pyridyl, 3-hydroxy-6-methyl-2-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, isothiazolyl -, oxazolyl, isoxazolyl, furazanyl, pyrrolidinyl, 2-pyrrolinyl, imidazolinyl, 2-imidazolinyl, pyrazolidinyl, 3-pyrazolinyl, piperidinyl, piperazinyl, morpholinyl, pyranyl, tetrahydropyranyl -, tetrazoyl, dioxanyl and dioxolanyl, which may be optionally mono- or polysubstituted, wherein the substituent may be hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, straight or branched branched, C 1 -C 6 alkoxy, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxyalkoxy (C 1 -C 6) alkyl or a linear or branched C 1 -C 6 polyhydroxyalkoxy (C 1 -C 6) alkyl group.

Particularly preferred groups are pyrrolidinyl, imidazolyl, oxazolyl, pyrrolyl, pyridyl, pyranyl, tetrahydropyranyl, furyl, dihydrofuryl, tetrahydrofuryl, dioxanyl, oxazinyl, thienyl, , morpholinyl, piperidinyl or dioxolanyl in which nitrogen is present

the atom may be optionally substituted with (C 1 -C 6) alkyl, straight or branched (C 1 -C 6) hydroxyalkyl, straight or branched (C 1 -C 6) polyhydroxyalkyl or straight or branched (C 1 -C 6) alkoxy. and wherein the heterocyclic ring may be optionally mono- or polysubstituted with hydroxyl, mercapto, C 1-6 alkyl and / or 1-6 hydroxyalkyl.

Preferred meanings of X with two fused rings include benzofuryl, iso-benzofuryl, chromenyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolinyl, phthalazinyl, quinazolinyl. , pteridinyl, isochromanyl, indolinyl or isoindolinyl, which may be optionally mono- or polysubstituted, wherein the substituent may be hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl, straight or branched C 1-6 alkoxy, straight or branched C 1-6 alkoxy (C 1-6) alkyl a linear or branched C 1-6 hydroxyalkoxy (C 1-6) alkyl group or a linear or branched (C 1-6) polyhydroxyalkoxy (C 1-6) alkyl -group.

Preferred meanings of Z include thiophenediyl, dihydrothiophenediyl, tetrahydro.

- 10-thiophenediyl, furandiyl, dihydrofuranediyl, tetrahydrofuranediyl, pyranediyl, dihydro-pyranediyl, tetrahydro-pyranediyl, pyrroleyl, 2H-pyrroleyl, dihydro-pyrroleyl, tetrahydro-pyrroleyl, imidazoldyl, pyrazoldyl, pyridinediyl, 3-hydroxy-6-methyl-2-pyridinediyl, pyrazindiyl, pyrimidindiyl, pyrazindiyl, thiazolyldil, isothiazolyldilyl, oxazoldyl, isoxazoldyl, furazandiyl, pyrrolidinediyl, 2 -pyrrolindyl, imidazolediyl, 2-imidazolindyl, pyrazolidinediyl, 3-pyrazolindyl, piperidinediyl, piperazindiyl, morpholindiyl, pyranediyl, tetrahydropyranediyl, tetrazoldyl, dioxanediyl, dioxolandiyl, benzo , iso (benzofuranediyl), chromenediyl, indole isoindilyl, purindilyl, quinolindilyl, phthalazindilyl, quinazolindilyl, pteridindiyl, isochromanediyl, indolyldilyl, isoindolyldilyl, indazolyldilyl, indolindylyl or isoindolyl.

In general, heterocyclic groups in which the heteroatom is in the β-position relative to the macrocycle nitrogen are preferred.

Among the functional groups which enable macromolecules to attach to the macrocycle or heterocyclic ring, the following may be mentioned in particular:

/ \

-ch ₂ -ch-ch ₂ , -ch ₂ -o- (ch ₂ ) ₄ -sh, -CH ₂ -O- (CH ₂ ) ₃ -nhn ₂ ,

II

-ch ₂ -o-ch ₂ -c-nh-nh ₂ , -ch ₂ -o-ch ₂ -ch ₂ -nh ₂ , oo

II II

-CH ₂ -O-CH ₂ -C-NH- (CH ₂ ) 10 ^-c_nh_nh 2 'ο

II

-CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₃ NH-C-CH-CH 3, -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₅ CO ₂ CH ₂ C ₆ H ₅ , ch ₂

-CH ₂ -C ₆ H ₄ -O-CH ₂ -CO ₂ -CH ₂ C ₆ H ₅ , -CH ₂ -C ₆ H ₄ -O (CH ₂ ) 5 CONHNH ₂ ,

II

-ch ₂ -c ₆ h ₄ -conhnh-c-ch-ch ₃ , -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₄ sh, ch ₂

-ch ₂ -c ₆ h ₄ -o (CH ₂ ) ₃ NHNH ₂ , -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₃ Br,

-CH ₂ -C ₆ H ₄ -O (CH _{2) 5} CONHNH- _(CH2) 3-NHNH _{2z -CH2} -SH, _-CH2 -NHNH- _2, - (CH _{2) 3} SH, _-CH2 - C ₆ H ₄ -O-CH ₂ -COBr, -C ₆ H ₄ NHCOCH ₂ Br, o

II

-CH ₂ -C ₆ H ₄ -OCH ₂ -C-NH- (CH ₂ ) ₂ NH ₂ , -ch ₂ -c ₆ h ₄ -nh ₂ , -c ₆ h ₄ -n ₂ ,

-c ₆ h ₄ ncs, -nhco-nh-nh ₂ , -ncs-nh-nh ₂ , o 0 0 / \ II II

-CH ₂ -C ₅ H ₄ -O-CH ₂ -CH-CH ₂ , -CH ₂ -C ₆ H ₄ -O-CH ₂ -C-NH (CH ₂ ) ₁₀ -C-NHNH ₂ ,

II

-CH ₂ -C ₆ H ₄ -O-CH ₂ -CHOH-CH ₂ -NH (CH ₂ ) ₁₀ -c-NH ₂ , ch ₃

II I

-OCH 2 CN-CH ₂ - (CHOH) ₄ -CH ₂ OH, (c), (cl), (c2), (d) or (dl) a group of formula.

Preferred ligands of formula (I) include those wherein W represents (d2), (e), (el), (e2), (e3), (e4), (f), (fi). , (g), (gl), (h), (h1), (h2), (h3), (i), (j) or (k).

Particularly preferred compounds of formula (I) are (Ia), (Ib), (Ic), (Id), (le), (If), (Ig), (Ih), (II), (Ij). , (Ik), (II), (lm), (In), (Io), (Ip), (Iq),

V «• ♦ · * · *% · • · 4 · · ·« • · · ·

- compounds of Formula 12 (Irish) and Is.

The macromolecules may be proteins such as albumin, antibodies, in particular monoclonal antibodies, antibody fragments, azyglycoproteins or polymers such as dextran or polylysine.

The ligands of formula I can be prepared by the following sequence of reaction steps:

a) a compound of formula IV

W - NH ₂ (IV) in which W is reacted with a compound of formula (V) above,

P- (CH) _m - (CH) _n -CH-NH-Ts III io m ^{r r r} 4 5 wherein R4, R5 and R _lo and m and n are as defined above,

P represents a leaving group which may be mesyloxy or tosyloxy or bromo, chloro or iodo; and

Ts is tosyl,

b) reacting the resultant compound of formula VII with a compound of formula VIII, wherein:

c) removing the tosyl group from the resulting compound of formula IX; and

d) alkylating the resulting compound.

To remove the tosyl group, compounds of formula IX can be reacted

- hydrobromic acid in acetic acid under reflux, as disclosed in WO 86/02352,

- concentrated sulfuric acid at 100 ° C as described in European Patent 287,465,

- with sodium dissolved in liquid ammonia (Helvetia Chimia Acta, 71, 685 (1988)), or

sodium in butanol at 100 ° C (Helvetia Chimica Acta 73: 716 (1990)).

Alkylation can be carried out

- either by reaction of the compound obtained in step c) directly with chloroacetic acid or chloroacetate as described in European Patent Specification 287 465, or

indirectly, the compound obtained in Step c) with an ester of α-bromoacetic acid or α-chloroacetic acid such as tert-butyl bromoacetate or tert-butyl chloroacetate in DMAC or DMF in the presence of a base in European Patent Application No. 299,795. or by reaction with ethyl bromoacetate in ethanol in the presence of cesium carbonate as described in J. Med. Chem. Soc. Chem. Commun. 1989, 794] followed by saponification of the resulting compound by a known saponification procedure or by using excess trifluoroacetic acid at room temperature in the case of tert-butyl esters as described in European Patent Application No. 299,795.

A group of compounds of formula II as defined above can be prepared by the following reaction steps:

a) a compound of formula IV

W - NH ₂ (IV) wherein W is as defined above, is reacted with a compound of formula X wherein

R ' ₂ is as defined above, and

P 'is tosyl, mesyl, phenylsulfonyl or 4-methoxyphenylsulfonyl,

b) reacting the resulting compound of formula XI with a compound of formula XII, wherein

R * 3 and P 'are as defined above,

c) reacting the resultant compound of formula XIII with a compound of formula XIV, wherein

P 'and R'i have the meanings given above,

d) removing the P 'from the resulting compound of formula XV to give compound of formula XVI, and

e) alkylating the compound of formula XVI.

Reaction steps a) and b) are carried out at 40 to 100 ° C in a solvent such as DMF, toluene or acetonitrile.

Step c) is carried out in DMF in the presence of sodium hydride at elevated temperature as described in Org. Synth., 58, 86-97 (1979)].

15 or dry DMF in a solvent at 40 to 80 ° C using cesium carbonate as described in the literature [J. Org. Chem., 49, (1984), 110-113] or by phase transfer catalysis.

The P 'removal and alkylation reactions can be carried out as described above for the preparation of compounds of formula (I).

The compounds of formula (XV) may also be prepared as follows:

a) reacting benzylamine with a compound of formula X described above to give a compound of formula XVII, wherein

_Bz is benzyl,

b) reacting the resulting compound of formula XVII with a compound of formula XII as described above to give a compound of formula XVIII,

c) reacting the resulting compound of formula XVIII with a compound of formula XIV to give a compound of formula XIX,

d) hydrogenating the resulting compound of formula XIX to give compound of formula XX; and

e) reacting the resultant compound of formula XX with a compound of formula W-P ', wherein

W is as defined above, and

P represents a group P 'or a chlorine atom or a bromine atom to give a compound of formula XV described above.

The reactions for the removal of the P * group and the alkylation are carried out as described above for the preparation of compounds of formula (I).

The amines of formula IV are known products and include 2-aminomethyl-1-ethylpyrrolidine, 2-aminoethyl-1-methylpyrrolidine, 2-aminomethylfuran, aminomethyl tetrahydrofuran and 2-methylaminopyridine, commercially available from Aldrich, or may be prepared as follows:

a) epoxidizing compound XXI with chloroperbenzoic acid as described in the literature (Journal of Pharmaceutical Sciences, 59, 1676-1679 (1970));

b) reacting the resulting compound with an azide such as sodium azide in aqueous methanol in the presence of ammonium chloride in a known manner (Tetrahedron Letters, 31, 5641-5644 (1990)) to give compound (XXII),

c) reduction of the resulting compound of formula XXII with palladium on charcoal in a known manner with hydrogen (Synthesis 4: 366-368 (1990)) to give the corresponding amine of formula XXIII.

The same procedure can be repeated in (XXVI)

- for the preparation of amines of formula XXXII starting from compounds of formula XXXIII to XXXIX.

Methods for preparing these compounds are described in detail in Normant and Castro, C.R. Acad. Sciences 259: 830 (1964); Ficini: Bull. Soc. Chim. Fr., (1956), 119-123; Mikailovic: Helv. Chim. Acta 56 (1973),

3056; Colonge and Buendia, C.R. Acad. Sciences, 261 (1965); Olsen, Chem. Beer, 91 (1958), 1589-1594).

The amine (XL) can also be prepared by reaction of 3-methylimidazole with formaldehyde to give compound (XLI) which is reacted with SOCl 2 to give compound (XLII) which is reacted with sodium azide the reaction product is catalytically hydrogenated.

Compounds of formula (X) and (XII) may be prepared by reacting a compound of formula (XXIV) wherein

R'2 and R'3 have the meanings given above,

With P'Cl, wherein

P 'is as defined above to give a compound of formula (XXV) which is reacted with aqueous potassium hydroxide in a known manner to produce a compound of formula (X) or (XII) (Helvetica Chimica Acta, 68, 289 (1985)), or reacting a compound of formula Xa with tosyl chloride in the presence of pyridine to give a compound of formula Xb.

The dimers of the ligands of formula (I) may be prepared in an analogous manner to that described above, namely

a) a compound of formula ^IVa

H ₂ N-W'-NH ₂ (IVa)

W 'is a group of formula (a3) wherein p and q and R 1 and R 2 are as defined above, and

X 'is a group of formula (11), (12), (13) or (14), and

_R6 and R7 together with the carbon to which they are attached, can optionally form a fused ring consisting of two, up to 12-membered heterocyclic ring, wherein 1-4 member heteroatoms such as O, -N = and / or the general Formula III R ^ N-group, where

R 8 is hydrogen, straight or branched C 1 -C 6 alkyl, straight or branched C 1 -C 6 hydroxyalkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, or straight or branched chain, C 1-6 -alkoxy, phosphorus or sulfur, the heterocyclic ring may be optionally mono- or polysubstituted, wherein the substituents are hydroxy, mercapto, straight or branched, C 1-6 alkyl, straight or branched, C 1-6 hydroxy. alkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxy; roxyalkoxy (C1-C6) alkyl, straight or branched (C1-C6) polyhydroxyalkoxy (C1-C6) alkyl, or functional groups thereof which allows the heterocyclic ring to be attached to a macromolecule with the proviso that when p and q are 0 then R'g and R'7 are

-CH ₂ - or -CH = or -CH- wherein ^R 10 is

R10 is reacted with a compound of formula (V) above,

b) reacting the resulting compound of formula (VIIa) with a compound of formula (VIII) above,

c) removing the tosyl groups from the resulting compound of formula IXa; and

d) alkylating the resulting compound.

The present invention relates to ion complexes, which are at least one ligand of the formula I having at least one metal ion such as lanthanide ion, transition metal ion, barium, bismuth, lead and / or ^99m Tc, ^11] · ⁹⁰ Y, ⁶⁴ Cu or l ⁶⁹ Yb radioisotopes form ^y ', and these complexes are formed with pharmaceutically acceptable inorganic or organic bases or basic amino acids

The X complexes contain one or more metals, preferably one or two metals, and have a neutral or ionic character.

The metal ions present in these complexes are preferably gadolinium, europium, dysprosium, iron (III), manganese (II) and / or barium.

Exemplary salts include salts with sodium hydroxide, N-methylglucamine, diethanolamine, lysine and arginine.

The complexes may be prepared by reacting the ligands with an aqueous salt or oxide of metals and, if necessary, forming a salt by neutralization.

It is understood that the present invention extends to the ligand-ether complexes of Formula I not only in the form of a racemic mixture, but also to the stereoisomers of these ligands and complexes.

From the ligands of the formula I, it is an invention

The complexes formed within the meaning of the present invention can be used in in vitro and in vivo diagnostic procedures in human and veterinary medicine.

The above complexes can be used as relaxation materials in nuclear magnetic resonance imaging and in vivo NMR spectroscopy; for this purpose, complexes with the following metals are preferred: Gd ^{3 +} , Mn 2+ and Fe ³⁺ ; complexes with Dy ^{3 +} , Ho ^{3 +} , Tb ³⁺ and Er ³⁺ metals are preferred as the material used for magnetic susceptibility testing; or complexes with metals Eu ³⁺ , Pr ³⁺ and Yb ³⁺ are preferred as chemical shifting agents.

In the field of X-ray radiology, complexes formed by the ligands of formula (I) with metals are preferred, the metals being preferably lanthanides,

La ^{3 +,} Bi ^2+, Ba ²⁺ and Pb ^2+.

The curing with nuclear radiation may be used complexes to consisting of ligand and ^99m of formula (I) Tc ΙΒ-Ιη 6 ⁴ Cu and 169yb metals radiodiagnostic procedures, while the ⁹⁰ Y, B-hn, ¹⁶⁹ Yb ²¹² Bi, ⁶⁴ Cu metal complexes linked to the corresponding molecules in the living body can be used in radiotherapeutic methods.

The complexes formed by the ligands of the formula I and preferably by the metal ions Eu ³⁺ and Tb ³⁺ can be used in in vitro diagnostic methods using photoluminescence such as immunofluorescence assays.

] ------- Based on the above, the present invention also relates to a human therapeutic composition comprising at least one complex comprising a ligand of the formula I with at least one metal ion such as lanthanide ion, intermediate metal ion, barium, bismuth, lead, ^99m Tc, Hlln, ⁹⁰ Y, 64 _{Cu, and} ¹⁶⁹ Yb radioisotopes, and salts of these complexes with pharmaceutically acceptable inorganic or organic bases or basic amino acids, wherein the complex is linked to a molecule or polymer in a living organism, or closed.

The present invention also relates to a therapeutic composition which is linked to a molecule or polymer in a living organism or to a lipo < g >

These compositions may contain the present invention

a solution of the complexes in a physiologically acceptable aqueous solvent.

The formulation of the present invention contains, in addition to at least one inventive tangle complex, a suitable ligand in the form of calcium or zinc in an amount of 0.05-10 mol%. .

The diagnostic compositions of the invention may be administered:

- parenterally, including intravenous, intra-arterial, subcutaneous and intravenous administration,

- orally,

- sub-arachnoidally and

- intrabronchially in aerosol form.

In the case of magnetic resonance imaging, the doses will be highly dependent on the route of administration.

The dose used for intravenous or intra-arterial administration is 0.01 to 2 mmol / kg.

For oral administration, this dose is up to 10 mmol / kg.

For other modes of administration, useful doses are generally less than 1 mmol / kg and generally less than 0.05 mmol / kg for sub-arachnoidal administration.

When used in in vivo spectroscopy as chemical shift inducer, NMR imaging, magnetic susceptibility modifier, and X-ray radiology contrast agent, dosages are the same except for intravenous or intra-arterial administration, where doses are in the range of 0.2 to 5 mm.

The following Examples illustrate the preparation of the compounds of the invention.

Example 1 - Preparation of a compound of formula (Ia)

a) Preparation of compound of formula XLIII

8.3 g (82 mmol) of tetrahydrofurfurylamine and 32.4 g (164 mmol) of tosyl aziridine are dissolved in 500 cm ^{3 of} dry toluene at 100 ° C. The mixture was stirred at this temperature for 20 hours. The reaction mixture was then filtered hot and the solvent was evaporated. The resulting oil was filtered through silica gel. After evaporation of the solvent, 28.4 g of a slowly crystallizing resinous product are obtained. Yield: 70%.

TLC: silica gel;

H ₂ Cl ₂ / ethyl acetate 90/10; Rf: 0.3.

b) Preparation of compound XLIV

9.9 g (20 mmol) of the product of step a) are dissolved in 1200 cm ^{3 of} dry DMF. After the reactor was placed under argon, 30 g of dry powdered Cs 2 CO 3 was added and the mixture was heated to 30 ° C. A solution of 11.35 g of N-tosylbis (2-tosyloxyethyl) amine in 300 cm ^{3 of} DMF was added dropwise. The reaction mixture was stirred until the starting materials disappeared. After completion of the reaction, the mixture was filtered and the solvent was evaporated under reduced pressure. The residue was taken up in 500 cm ^{3 of} dichloromethane. The chloromethylene solution was filtered and washed three times with water. After drying over anhydrous magnesium sulfate, the dichloromethane is evaporated. The mara24 decane was purified by chromatography on silica gel. 7 g (49%) of pure product are obtained.

TLC: silica gel; CH 2 Cl 2 / ethyl acetate 95/5; Rf: 0.4.

¹³ C NMR: 150-130 ppm, aromatic, tosyl; 80, 71.8, 53, 34.8 and 29.8 ppm, tetrahydrofurfuryl units; 61-53 ppm, macrocyclic ring, 26, 24 ppm, CH3 of tosyl.

c) Preparation of XLV

5 g of the product obtained in step b) are added to 250 cm ^{3 of} dry n-butanol. The mixture was stirred under a dry nitrogen atmosphere and heated to 100 ° C. After complete dissolution of the starting material, 15 g of sodium are added in small portions. After the addition was complete, the butanol was evaporated and the residue taken up with water. The aqueous solution was concentrated and the residue was taken up in absolute ethanol.

After evaporation of the ethanol, the product is taken up in dichloromethane and the salts are removed by filtration. The chloromethylene solution was evaporated and the resulting oily residue was dissolved in 200 cm ^{3 of} 1 M hydrochloric acid. The acidic solution is evaporated to dryness. After drying, 1.8 g of product are obtained in the form of the hydrochloride.

TLC: silica gel / water / ammonia: 8/3/2; Rf: 0.1.

VI

d) Preparation of compound XLf ¥

580 mg of product of step c) and 1.5 g of sodium bicarbonate are suspended in 40 cm ^{3 of} dry DMF. An argon atmosphere was created in the reactor and the mixture was heated to 50 ° C. Then 1 cm ^{3 of} space 25

butyl bromoacetate and 10 cm ^{3 of} dry DMF solution are added dropwise. After 24 hours, DMF was evaporated under reduced pressure. The product is then dissolved in dichloromethane and the salts are isolated by filtration. Evaporation of the dichloromethane gave a yellow oil which was purified by chromatography on silica gel. 650 mg of a slowly crystallizing pure product are obtained.

TLC: silica gel; CH 2 Cl 2 / methanol 10%; Rf: 0.5.

IR: 1710 cm -1 carbonyl band, ⁺ NMR: 1.43 ppm, s 2 singlet, tert-butyl,

13c NMR: 173 ppm, carbonyl; 83 ppm quaternary C tert-butyl; 28 ppm, methyl ester; 74, 69, 30, 26 ppm, tetrahydrofuran unit.

MS: MH ⁺ 559.

e) Preparation of a compound of formula la

The operation rooms 650 mg was dissolved in ca 10 ^J trifluoroacetic acid. The mixture was stirred at room temperature for 24 hours. The trifluoroacetic acid is then evaporated and the residue is concentrated with water. The product is then purified on IRA 458 OH 'resin. Finally, 150 mg of product are obtained.

TLC: silica gel; ethyl acetate / isopropanol / ammonia: 12/35/30; Rf: 0.6.

13c NMR: 170 ppm, carbonyl; 74, 65, 27, 22 ppm, tetrahydrofuran unit.

Mass Spectrum: M ⁺ 431.

The gadolinium complex of the compound described above was prepared by using (4 mmol) of Gd

The crude product obtained (8 mmol) was suspended in 100 ml of water at 80 ° C and stirred for 24 hours.

The solution was cooled to room temperature and the solvent was evaporated under reduced pressure.

The resulting solid was dissolved in 15 mL of water and 5 mL of ethanol and added dropwise to 750 mL of rapidly stirred acetone.

The resulting precipitate was filtered, washed with acetone and dried at room temperature under vacuum.

Example 2 - Preparation of Compound of Formula Im

a) Preparation of compound (XLVII) g (40 mmol) of monobenzyltritosylcyclene prepared according to the procedure described in European Patent 255,471 was reduced to 500 cm ^{3 of} acetic acid under hydrogen pressure at 4 x 10 ⁵ Pa. The mixture was stirred for 24 hours at 70 ° C. After filtration, the solvent was evaporated. The resulting solid solution was washed successively with potassium carbonate solution and then water. 23.7 g of a white powder are obtained.

TLC: SiO ₂ , CH ₂ Cl ₂ / CH ₃ OH (95/5), R f: 0.3; op. =

195 ° C. Yield: 93%.

b) Preparation of compound (XLVIII): g (7.8 mmol) of tritosylcycline prepared in step a), 1.45 g (8.6 mmol) of 2-chloromethyl-1-methylimidazole prepared in the literature [ PC Jocelyn, J. Chem. Soc., (1957), 3305] and 2.7 cm ³ (197 mmol) of triethylamine in 50 cm ^{3 of} dichloromethane. The reaction mixture

- Reflux for 27 hours. To the solution was added 1.45 g (8.6 mmol) of chlorinated reagent. The reaction mixture was refluxed for 12 hours. In 10 ^cm3 of dichloromethane, 1.35 cm ³ (9.85 mmol) of triethylamine were added to the reaction mixture and heated for another 12 hours in a reflux. After cooling, the triethylamine is removed by washing with water. The organic phase, dried over anhydrous magnesium sulfate, is concentrated and purified by chromatography on silica gel. 6 g of a white powder are obtained.

Yield: 53%.

1 H NMR (DMSO) S, 2.41 ppm: 2s, ch ₃ δ = 2.65 ppm: m. ch ₂ 3.05 ppm < δ = 3.7 ppm: m. ch ₂ 6.7 ppm < δ = 7.05 ppm: d. CH = CH 7.4 ppm < δ = 7.75 ppm: m. CH = CH.

c) Preparation of the compound of formula (IL) The substrate prepared in step b) (g, 8.3 mmol) was dissolved in 80 cm ^{3 of} dry n-BuOH. The solution was heated to 100 ° C under inert atmosphere. Sodium (5 g, 220 mmol) was added very slowly to the solution. The solution was then heated at 100 ° C for 12 hours and the solvent was evaporated. The product was taken up several times with water and dried and extracted with dichloromethane (3 x 20 cm ³ ). The solvent was evaporated and the residue was dissolved in 50 cm ^{3 of} 6N hydrochloric acid. The solution was concentrated and washed 3 times with 15 cm <^{3> of} dichloromethane. After drying, 2.9 g of product is isolated as hydro28 chloride.

TLC: SiO ₂ , CHCl 3 / CH 3 OH / NH 4 OH (4/4/2), R f: 0.3.

d) Preparation of a compound of formula (L)

2.2 g (5.8 mmol) of the product of step c) and 6.3 g (58 mmol) of sodium carbonate are suspended in 35 cm ^{3 of} dry DMF. The mixture was heated to 60 ° C under inert atmosphere. 3.75 g (19.2 mmol) of tert-butyl bromoacetate in 35 cm ^{3 of} DMF are added dropwise. After a reaction time of 24 hours, the DMF was evaporated. The product was taken up in 100 cm ^{3 of} dichloromethane and washed 3 times with 70 cm ^{3 of} water. The organic layer was dried over anhydrous magnesium sulfate, concentrated and purified by chromatography on silica gel. After evaporation of the solvent and drying, 1.4 g of a white powder are isolated.

Yield: 40%.

TLC: SiO ₂ , CH ₂ Cl ₂ / EtOH (90/10), Rf: 0.5.

IRISH (KBr): 1720 cm ~ 1 C = 0th H ⁺ NMR (DMSO): 8 = 1.4 ppm: 2s, C (CH ₃ ) ₃ 2 < 8 - 3.5 ppm: m. ch ₂ = ch 6.5 < 8 = 7.05 ppm: d. CH = CH ¹³ C NMR (DMSO): 8 = 27.4 ppm: ch ₃ 8 = 31.7 ppm: ch ₃ 6 = 48.9 ppm: ch ₂ 8 = 55.0 ppm: ch ₂ 8 = 55.7 ppm: ch ₂ 6 = 80.9 ppm: c

= 121.0 ppm: HC = CH

- 29 - δ = 125.5 ppm: HC = CH δ = 146.0 ppm: C = N δ = 171.6 ppm: C = O δ = 172.3 ppm: C = O Mass Spectrum (FAB) m / z 632 (M + Na ⁺ ).

e) Preparation of the compound of formula (1m) g (1.64 mmol) The product of step (d) was dissolved in 40 cm ^{3 of} trifluoroacetic acid. The solution was stirred at room temperature for 20 hours under inert atmosphere. The trifluoroacetic acid is then evaporated and removed as an azeotropic with water. The crude product was purified on IRA 458 resin. 600 mg of white powder were isolated. Yield: 83%.

IR (KBr): 3450 cm ^-1 OH

1650 cm ^- } · C - 0.

H ⁺ NMR (DMSO): 2.6 <δ = 4 ppm: m, CH ₂ and CH ₃ 6.8 <δ = 7.1 ppm: d CH = CH δ = 7.4 ppm: m, OH ¹³ C NMR (DMSO): δ = 32.7 ppm: ch ₃ δ = 49.6 ppm: ch ₂ δ = 51.2 ppm: ch ₂ δ = 54.8 ppm: ch ₂ <5 = 122.0 ppm: CH = CH δ = 125.7 ppm: CH = CH δ = 144.0 ppm: C = N δ = 170.1 ppm: 2C = O δ = 171.1 ppm: 1C = O

Example 3 - Preparation of a compound of formula (Irish)

a) Preparation of 2: 5-ditosyl-1,4: 3,6-dianhydrosorbitol of formula (LI)

Commercially available as isosorbide (available from Aldrich Chimie, Strasbourg), 1,4: 3,6-dianhydro-D-sorbitol is prepared from 2: 5-ditosyl-1,4: 3,6-dianhydro-sorbitol by the method described in the literature [ J. Chem. Soc., 68, (1946) 927 and J. Chem. Soc., (1946) 393].

Yield: 213 g (100%), based on 100 g of isosorbide starting material. TLC: SiO ₂ , eluent CH ₂ Cl ₂ / AcOEt: 97/3, Rf: 0.6.

b) Preparation of 2: 5-diazido-1,4: 3,6-dianhydrosorbitol

From the compound obtained in the preceding step, 2: 5-diazido-1,4: 3,6-dianhydro-sorbitol was prepared according to the literature procedure (Carbohydrate Research 85: 259 (1980)).

The product obtained from 150 g of the compound obtained in the previous step weighs 37 g; yield: 57%; TLC: SiO ₂ ; eluant: petroleum ether / ethyl ether 85/15; Rf: 0.25.

IR: 2100 cm ^-1 ; azidsáv.

c) Preparation of 2: 5-diamino-1,4: 3,6-dianhydrosorbitol

4.5 g (22.95 mmol) of the compound obtained in the previous step are dissolved in 200 cm ^{3 of} ethanol at 95 ° C. To the solution was added 1 g of palladium on charcoal and the suspension was subjected to an autoclave at 50 ° C for 13 to 14 x 10 ⁵ Pa of hydrogen pressure. The reaction mixture was stirred for 7 hours at constant hydrogen pressure and allowed to stand overnight at the remaining hydrogen pressure.

The reaction mixture was filtered and the solvent was evaporated. The resulting oily residue is taken up in acetonitrile and the white precipitate formed is removed by filtration.

The resulting solution was evaporated to give 3.3 g of a colorless oil.

Yield: 100%.

IR: disappearance of the azide band at 2100 cm -1. NH bands at 3360 and 3280 cm -1.

¹³ C NMR: 55.67 ppm - 59.17 ppm - 72.41 ppm - 75.58 ppm - 82.33 ppm - 92.68 ppm.

TLC: SiO ₂ ; eluent CH ₂ Cl ₂ / MeOH / NH ₃ : 16/4 / 0.1.

Rf: 0.37.

d) Preparation of a compound of formula LII

5 g (34.7 mmol) of the compound obtained in the previous step dissolved in 250 cm ^{3 of} acetonitrile and 27.3 g (0.139 mole) of tosyl aziridine are introduced into a 500 cm ³ three-necked round bottom flask. The mixture was stirred at 70 ° C for 4 days. The solvent was evaporated under reduced pressure and the residue was purified on a silica gel column.

The expected product is obtained in a yield of 52%.

TLC: SiO ₂ ; CH ₂ Cl ₂ / MeOH: 95/5. Rf = 0.35.

IR: 3250 cm ^-1 ; HN-Ts.

• «

e) (LIII) A solution of Compound g product obtained (16.1 mmol) of the preceding step, 750 cm ³ of dry DMF and 32 g of anhydrous cesium carbonate were introduced in a 2 liter, three-neck flask under argon. To the mixture was slowly added tosylated bis-ethanolamine (18.25 g, 32.18 mmol) in 200 cm ^{3 of} DMF. The mixture was heated at 40 ° C for 3 days. The solution was then filtered and the DMF was evaporated. The compound was purified on a silica gel column.

g of the title compound is obtained, corresponding to a 36% yield.

TLC: SiO ₂ ; CH ₂ Cl ₂ / AcOEt: 90/10, R f = 0.65.

4 H NMR: 7.4-7.8 ppm, multiplet: aromatic hydrogen, tosyl group hydrogen, 2.4 ppm, singlet: methyl, tosyl.

f) Preparation of the compound of formula LIV: The product obtained in the previous step (g) (2.91 mmol) was added to 350 cm ^{3 of} dry n-butanol. The mixture was heated to 110 ° C with stirring. The reactor was purged with dry nitrogen and 20 g of sodium was added in small portions over a period of 8 hours.

Subsequently, the temperature was lowered to 80 ° C and the reaction mixture was stirred overnight.

After complete removal of the butanol, the oily residue was taken up in 1M aqueous hydrochloric acid. The solution was filtered and washed with dichloromethane.

After evaporation, the amine hydrochloride was obtained as a white solid (2 g).

TLC: SiO2; H2Cl ₂ / MeOH / aqueous ammonia: 4/4/2, Rf = 0. 1 ³ C NMR: 40.72 ppm - 48.42 ppm for hydrogen macrocycles; 63.89 ppm - 66.03 ppm 66.40 ppm - 70.16 ppm - 82.05 ppm - 83.25 ppm, central bis-heterocycle unit.

q) Preparation of Compound (LV) 3.9 g of the product obtained in the previous step dissolved in cm ^{3 of} acetonitrile are introduced into a 500 cm ^{3 3-} necked round-bottom flask equipped with a condenser and magnetic stirrer and placed under an argon atmosphere.

15 g of anhydrous sodium carbonate are added with ³ ml of acetonitrile.

The mixture was stirred and heated to 40 ° C.

Subsequently, 10.8 g of tert-butyl bromoacetate dissolved in 30 cm ³ of acetonitrile is added dropwise.

After 24 hours, the mixture was filtered and the filtrate of the reaction mixture was concentrated. The resulting oil was taken up in ethyl ether.

The resulting solid was washed several times with ether. Purification on a silica gel column gave 5.6 g of the title compound.

TLC: ₂ S10; CH ₂ Cl ₂ / MeOH: 90/10, R f = 0.4.

FAB mass spectrum (glycerol) MH ⁺ Na ⁺ 162.

h) Preparation of a compound of formula (Irish)

The product obtained in the preceding step was dissolved in 30 cm ^{3 of} trifluoroacetic acid.

The reaction mixture was stirred at room temperature for 16 hours. The solvent was evaporated and the residue was taken up in water.

The resulting solution was concentrated. The product was purified on IRA 458 resin.

TLC: SiO2; AcOEt / isopropanol / aqueous ammonia:

12/35/30, Rf = 0.25 + 0.42.

FAB mass spectrum (glycerol) MH ⁺ 803.

¹³ C NMR: 171.9 ppm - 171.6 ppm - 167.4 ppm - carbonyls.

57.55 ppm - 61.23 ppm - 62.57 ppm - 68.80 ppm 79.18 ppm - 80.10 ppm: central heterocyclic system;

53.9 ppm: methylene of carboxymethyls;

50.62 ppm - 41.67 ppm: macrocyclic rings.

Example 4 - Preparation of compound of formula (Is)

a) Preparation of 2: 5-ditosyl-1,4: 3,6-dianhydromannitol (LVI)

The title product is prepared from 73 g (0.5 mol) of 1,4: 3,6-dianhydro-D-mannitol, commercially available as Isomannide (available from Aldrich Chimie, Strasbourg) according to the procedure described in the literature. Organometallic Chemistry, 253, 249-252 (1983)].

Yield = 196.2 g, 86.5% yield.

b) Preparation of 2: 5-diazido-2,5-dideoxy-1,4: 3,6-dianhydroiditol

98 g (0.2 mol) of the title compound <1

Prepared from 35 compounds obtained by the known method (Carbohydrate Research 85: 259-269 (1980)).

Yield: 36 g (85%).

c) Preparation of 2: 5-diamino-2,5-dideoxy-1,4: 2,6-dianhydroiditol

The title compound was prepared from 12 g (0.06 mol) of the compound obtained in the preceding step by the procedures described in JACS 78, 1956, 3180 and Synthetic.

Communications 19: 1493-1498 (1989)].

Weight: 9 g.

d) Preparation of compound LVII

The product obtained in the preceding step (8.8 g, 0.06 mol) was dissolved in acetonitrile (800 ml) in the presence of N-tosyl aziridine (48.15 g, 0.244 mol).

The reaction mixture was refluxed for 48 hours. The mixture was evaporated to dryness for subsequent column chromatography. 26.1 g of product are obtained, corresponding to a yield of 51%.

TLC: (CH ₂ Cl ₂ 95 / AcOEt 5 / MeOH 5): R f = 0.5.

1 H NMR (200 MHz) (DMSO): 2.3 ppm, CH ₃ tosyl 7.3 and

7.6 ppm, aromatic H.

¹³ C NMR 128, 130, 138 and 143 ppm, aromatic C, 85, 70, ppm, C, 22 ppm for the central bis-heterocyclic system, C for the CH3 - group of the tosyl group.

e) Preparation of compound LVIII: g (0.0322 mol) of the product obtained in the previous step

Dissolve in 1.8 liters of anhydrous DMF 94 g of cesium carbonate * ··· • · •

- in the presence of 36 under argon at 40 ° C. After 1 hour, a solution of 36.6 g (0.0645 mol) of tritosylated diethanolamine in 0.9 L of DMF was added slowly to this suspension.

The reaction mixture was heated at 40 ° C for 48 hours. After filtration and evaporation of the DMF, the resulting residue was subjected to column chromatography.

The procedure described gives 16 g of product which corresponds to a% yield.

TLC: SiO ₂ ; CH ₂ Cl ₂ 95 / AcOEt 4 / MeOH 1: Rf = 0.15.

IR (KBr disk): disappearance of the NH-Ts bond at 3300 cm &lt; -1 &gt;.

¹³ C NMR (200 MHz) (DMSO): 128, 130, 138 and 143 ppm, aromatic C,

83.68 and 66 ppm, C, ppm and unbroken bands for the central bis-heterocyclic system at 50 ppm, C, ppm for the two rings formed, and CH _{3 for the} tosyl group.

(f) Preparation of compound (LIX) g of the product obtained in the previous step (0.0116 mole) was dissolved in 840 ml of n-butanol previously heated to reflux. Sodium (73.6 g, 3.2 mol) was added slowly to this solution. The reaction mixture was heated at 80 ° C for 12 hours. After complete removal of the solvent, the product is taken up in 300 ml of hydrochloric acid. The resulting solution was washed twice with dichloromethane. The aqueous phase is evaporated to dryness. 7.0 g of the title product t

37 yields 90% yield.

TLC: SiO ₂ ; CH ₂ Cl ₂ 4 / MeOH 4 / NH ₄ OH 2: R f = 0.1 (developing with I ₂ ).

¹³ C NMR (DMSO): 83.68 and 66 ppm, C for the central heterocycle

44, 42, 38 and 37 ppm, C. of the bicyclic groups.

q) Preparation of the compound of formula LX (g) (0.00886 mole) of the product obtained in the previous step was suspended in 150 ml of CH ₃ CN at 18.degree. C. in the presence of 18.8 g (0.177 mole) of sodium carbonate. To the mixture was added dropwise a solution of BrCH ₂ COOtBu (13.8 g, 0.070 mol) in CH ₃ CN (80 mL). The reaction mixture was stirred at 40 ° C for 72 hours. After filtration, the solution was concentrated. The expected product crystallizes. After filtration and washing with ether, 8.3 g of the title product are obtained, corresponding to a yield of 77%.

TLC: SiO ₂ ; CH ₂ Cl ₂ 85 / MeOH 15: R f = 0.6.

IR: 1710 cm -1, carbonyl band.

NMR: 1.4 ppm singlet, tert-butyl.

¹³ C NMR (DMSO) 175 ppm, belonging to the carbonyl group

C, ppm, quaternary C from tert-butyl, ppm, CH ₃ ,

63.68 and 80 ppm, central bis-heterocyclic system.

h) Preparation of a compound of formula (Is)

0.3 g (0.0073 mole) of the product obtained in the previous step • V

- 38 Dissolve in 130 ml of trifluoroacetic acid at room temperature. After 12 hours, the reaction mixture was concentrated, taken up in water and evaporated.

The product was purified on IRA 458 resin.

TLC: Sic> 2; AcOEt 12 / isopropanol 35 / NH 4 OH 30: R f =

0.2 + 0.35.

¹³ C NMR: 167 and 172 ppm, acid C,

63, 68 and 80 ppm, central heterocyclic system, ppm, multiplet CH _{2 at} α-position relative to COOH, δ ≤ 50 ppm, C-FAB mass spectrum (glycerol) for the two rings, MH ⁺ 803.

Example 5 Preparation of compound of formula (If)

a) Preparation of 3,4-epoxy-tetrahydrofuran

The title product is prepared from 58 g (0.83 mol) of 2,5-dihydrofuran, commercially available from Aldrich Chimie, Strasbourg, according to the procedure described in the literature (Journal of Pharmaceutical Sciences, 59, 1676 (1970)). -1679].

The product weighed 54 g. Yield: 71%.

b) Preparation of 3-hydroxy-4-azido-tetrahydrofuran

The title product was prepared from 54 g (0.63 mol) of the product obtained in the preceding step by the procedure described in Tetrahedron Letters 3, 5641-5644 (1990).

Weight: 73 g. Yield: 90%.

c) Preparation of 3-hydroxy-4-amino-tetrahydrofuran

The title compound was prepared from the product of the preceding step (24 g, 0.19 mol) in Synthesis 4, 366-368 (1990).

Weight of product: 20 g.

d) Preparation of LXI Compound g (0.097 mol) of the product obtained in the previous step was stirred in acetonitrile (600 ml) with N-tosyl aziridine (38.2 g, 0.19 mol) at 50 ° C for 72 hours. The solution was concentrated and the resulting residue was crystallized from ethyl acetate / toluene.

After filtration, washing and drying, 31 g of product is obtained, corresponding to a yield of 64%.

TLC: SiO ₂ ; CH ₂ Cl ₂ 90 / MeOH 10: R f = 0.5.

1 H NMR (200 MHz) (DMSO): 2 doublets at 7.4 and 7.7 ppm, aromatic protons, ppm, OH, protons of the heterocyclic rings: singlet at 4 ppm, multiplet 3.7 and 3.4 ppm <8 <3 ppm, CH ₂ CH ₂ CH 3 and (Ts).

e) Preparation of Compound (LXII): The product obtained in the preceding step (g) (0.0362 mol) was dissolved in DMF (1200 ml) in the presence of cesium carbonate (54 g, 0.165 mol) at 40 ° C under argon.

To the prepared solution was added a solution of 20.6 g (0.0363 mol) of tritosylated diethanolamine in 600 ml of DMF.

After completion of the reaction, the reaction mixture is filtered and concentrated.

The residue was subjected to column chromatography. Yield: 15 g (58%).

• · «··

TLC: SiO ₂ ; CH ₂ Cl ₂ 95 / MeOH 5: R f = 0.2.

IR (KBr) 3300 cm ^-1 , NHT 5.

Ifi NMR (DMSO) aromatic protons:

7.6 ppm triplet,

7.4 ppm doublet,

5.1 ppm, doublet, OH, tetrahydrofuran protons: 4.1 ppm, singlet, <5 <3.9 ppm (unbroken bands).

f) Preparation of compound LXIII

The product obtained in the previous step (20.5 g, 0.028 mol) was dissolved in n-butanol (440 ml) under reflux.

Sodium (32.0 g, 1.4 mol) was added slowly to the reaction mixture and heated to 80 ° C with stirring.

After the butanol was removed with water, the residue was taken up in 300 ml of 1N hydrochloric acid. The resulting solution was washed with dichloromethane and evaporated to dryness.

g of product is obtained;

TLC: SiO ₂ ; CH ₂ Cl ₂ 4 / MeOH 4 / NH ₄ OH 2: R f = 0.1 (I ₂ ).

¹³ C NMR: 84-72-69 and 67 ppm, tetrahydrofuran C, and 42 ppm, ring C.

g) Preparation of compound LXIV: The product obtained in the preceding step (g) (0.14 to 7 moles) was suspended in acetonitrile (1.5 liters) in the presence of sodium carbonate (155.5 g, 1.46 moles) at 40 ° C.

To the reaction mixture was slowly added 114.5 g (0.6 mole) of tert-butyl bromoacetate in 0.7 L of acetonitrile. . ··

* .. '··' ····: ·· ·· ·.

41 solution, then filtered, and the filtrate was concentrated to dryness. The resulting residue was crystallized from ethyl ether and subjected to column chromatography (69 g). Yield: 72%.

TLC: SiO ₂ ; CH ₂ Cl ₂ 80 / MeOH 20; Rf = 0.6.

IR (KBr) 1710 cm ^-1 , C = O.

¹³ C NMR: 170 and 173 ppm, carbonyl C, ppm, quaternary C,

84, 72, 69 and 67 ppm, tetrahydrofuran C, ppm, in the CH ₂ chain of the ester at the α-position

C

52, 49 and 46 ppm, ring C, ppm, CH3 in the tert-butyl group.

h) Preparation of compound (If) g (0.063 mol) of the product obtained in the preceding step

Dissolve in 600 ml of trifluoroacetic acid at room temperature.

After 1 h, the reaction mixture was concentrated to dryness and the residue was taken up in water. Purification on IRA 458 resin gave 20 g of product. Yield: 73%.

TLC: SiO ₂ ; AcOEt 12 / isopropanol 35 / NH 4 OH 30: R f = 0.45 and 0.5.

¹³ C NMR: 170 ppm C = 0,

73, 72, 69 and 67 ppm, tetrahydrofuran C, ppm, C for the CH ₃ chain member in the a-position relative to the COOH, C ppm δ <45 ppm for the ring.

Mass Spectrum: FAB (glycerol) MH ⁺ 433.

Example 6 - Preparation of compound of formula (It)

a) Preparation of Formula (LXV)

0.7 g (2.7 mmol), 0.7 g of paraformaldehyde and 2.5 g (16.2 mmol) of the compound obtained in Example 1 (c) above are prepared according to the procedure described in Organic Preparations and Procedures Int. 11-16 (1979)] was heated to reflux for 12 hours in THF (30 ml).

After concentration, the solution is chromatographed on alumina, eluting with dichloromethane.

0.5 g of a pale yellow oil are obtained, corresponding to a yield of 30%.

TLC: SiO ₂ ; CH ₂ Cl ₂ / MeOH: 90/10,

Rf = 0.2.

b) Preparation of a compound of formula (It)

0.5 g (0.8 mmol) of the compound obtained in the previous step is refluxed in 6 ml of 6N hydrochloric acid for 12 hours.

After concentration, the product is purified on silanized silica gel.

0.25 g of the title compound is obtained, corresponding to a yield of 42%.

TLC: SiO ₂ ; dioxane / water / NH3: 8/3/2.

Claims (23)

PATENT CLAIMS Ligands of formula (I), wherein 2, A _2r A ₃ and A ₄ are each independently represented by the formula (a) wherein m and n are each independently an integer from 1 to 5, R ₄ and R 5 are each independently hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, or polyhydroxyalkyl; a functional group which allows the attachment of the macrocycle of formula I to a macromolecule; linear or branched C 1-6 alkoxy (C 1-6) alkyl, straight or branched hydroxy (C 1-6) alkoxy (C 1-6) alkyl, or straight or branched polyhydroxy; - (C 1 -C 6) alkoxy (C 1 -C 6) alkyl, aryl or mono- or polysubstituted aryl, wherein the substituents are independently halogen, hydroxy, nitro or (C 1 -C 6) alkyl, (C 1 -C 6) hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy or C 1-6 alkoxy (C 1-6) alkyl, aralkyl or mono- or polysubstituted aralkyl, wherein substituents independently of one another may be halogen, hydroxy, nitro or C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy or C 1-6 -alkoxy (C 1-6) -alkyl, wherein the alkyl in the aralkyl is a straight or branched C 1-6 -alkyl, R10 is R4 or R5, hydroxy or C1-C6 alkoxy, Rl, _R2 and _R3 are independently hydrogen or Rg Rg Rg Rg Rg Rj3 Ilii I I -CH-COOH, -CH-PO ₃ H ₂ , -CH-COO, -CH-PO ₃ - or -CH-PO ₂ -, wherein Rg is hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl, or straight or branched C 1-6 alkoxy (1-6C) alkyl; C 6 alkyl), and R 13 is straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl or polyhydroxyalkyl, straight or branched C 1-6 alkoxy (1-6). C 1 -C 6 alkyl or straight or branched C 1 -C 6 hydroxyalkoxy or polyhydroxyalkoxy (C 1 -C 6) alkyl, B is a group of formula N-W, wherein W is a group of formula (Ia) wherein p and q are each independently an integer from 0 to 6, R11 and R12 independently of one another have the same meaning as R10 when p is different from O, and have the same meaning as R4 and R5 when p is 0, and X is a group of formula (b) or (b1) wherein R ₆ and R _7, with the carbon atom to which they are attached, optionally form a heterocyclic ring of up to 12 membered fused rings, with 1 to 4 membered heteroatoms, such as oxygen, -N = and / or N-R 8. , in which R 8 is hydrogen, straight or branched C 1 -C 6 alkyl, straight or branched C 1 -C 6 hydroxyalkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, or straight or branched chain, C 1-6 alkoxy, phosphorus or sulfur, the heterocyclic ring may be optionally mono- or polysubstituted, wherein the substituents are hydroxy, mercapto, straight or branched, C 1-6 alkyl, straight or branched, C 1-6 hydroxy. alkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxyalkoxy - (C 1-6) alkyl, straight or branched (C 1-6) polyhydroxyalkoxy (C 1-6) alkyl or functional groups which permit the attachment of the heterocyclic ring to a macromolecule, provided that when p and q are 0, R ₈ and R ₇ are -CH 2 - or -CH = or -CH-, wherein ^R 10 ^R 10 is as defined above; obsession W is (a-2) a group of formula wherein p, q, R _{lz R2,} R3, R11, R12, Αχ, A _2, A ₃ and A ₄ are as defined above, and Z is optionally a two-membered heterocyclic ring of up to 12 membered fused rings wherein 1-4 membered heteroatoms, such as oxygen, -N = and / or &lt; NR ₈ &gt; Rg is as defined above, -phenyl, the heterocyclic ring may be optionally mono- or polysubstituted, wherein the substituents are hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxy. -alkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxyalkoxy (C1-C6) alkyl, straight or branched (C1-C6) polyhydroxyalkoxy (C1-C6) alkyl, or functional groups which allow the heterocyclic ring to be attached to a macromolecule, 1-je flax Designation · 0 to 5 integer with the proviso that R ₂ and R _lz R3 least two of R R ₉ rg -CH-COOH, -CH-PO3H2, -CH-COO ^- , -CH-PO3- R 8 is R ₁₃ or -CH-PO ₂ ^{- in} which R8 and R13 are as defined above; and Αχ, _{R2, R4, R5,} Rg, Rg, Rio, & 11, ^ 2 ^{and R13} can be different from Rec., R2, R4, R5, Re, R _9, R _lo, ^R II · ^r 2 · and R13 when 1, m, n and q are other than O, or when several of the above groups are present, and salts of these compounds with inorganic or organic bases or basic amino acids. Ligands of formula I according to claim 1, wherein ₂ , A ₂ , A ₃ and A 4 are each independently of the formula (a) wherein m and n are each independently an integer from 1 to 5, R 4 and R 5 are each independently hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, or polyhydroxyalkyl; a functional group which allows the attachment of the macrocycle of formula I to a macromolecule; linear or branched C 1-6 alkoxy (C 1-6) alkyl, straight or branched hydroxy (C 1-6) alkoxy (C 1-6) alkyl, or straight or branched polyhydroxy; (C 1-6) alkoxy (C 1-6) alkyl, aryl or mono- or polysubstituted aryl, wherein the substituents may be independently halogen, hydroxy, nitro or C 1-6 alkyl, C 1-6 hydroxy; alkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy or C 1-6 alkoxy (C 1-6) alkyl, aralkyl or mono- or polysubstituted aralkyl, wherein the substituents are independently selected from halo, hydroxy, nitro or C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy or C 6 -C 6 alkoxy-C 1 -C 6 -alkyl, wherein the alkyl group in the aralkyl group is a straight or branched C 1 -C 6 alkyl group, R10 is R4 or R5, hydroxy or C1-C6 alkoxy, Rl, _r2 and R3 are each independently hydrogen, Rg Rg Rg Rg III I -CH-COOH, -CH-PO3H2, -CH-COO ^- or -CH-JD3 -, wherein R 8 is hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl or straight or branched, -C 6 -alkoxy (C 1 -C 6) -alkyl, B is a group of the formula N-W wherein W is a group of formula (Ia) wherein p and q are independently 0 to 6, Ri! and Rj2 independently of one another R _lo report, when p is other than 0, and has the same meaning as R4 and _R5, when p is 0, and X is a group of formula (b) or (b1) wherein R8 and R7, taken together with the carbon atom to which they are attached, optionally form a heterocyclic ring of up to 12 membered two fused rings wherein 1-4 membered heteroatoms such as oxygen, -N = and / or N-R8, wherein R ₈ is hydrogen, straight or branched C 1 -C 6 alkyl, straight or branched C 1 -C 6 hydroxyalkyl, straight or branched C 1 -C 6 polyhydroxyalkyl, or straight or branched chain C 1-6 -alkoxy, phosphorus, or sulfur, the heterocyclic ring may be optionally mono- or polysubstituted, wherein the substituents are hydroxy, mercapto, straight or branched, C 1-6 -alkyl, straight or branched, C 1-6 hydroxyalkyl, straight or branched, C 1-6 polyhydroxyalkyl, straight or branched, C 1-6 alkoxy (C 1-6) alkyl, straight or branched, 1-6 C 1-6 hydroxyalkoxy (C 1-6) alkyl, straight or branched (C 1-6) polyhydroxyalkoxy (C 1-6) alkyl, or functional groups which allow the attachment of the heterocyclic ring to a macromolecule, provided that when p and q are 0, R ₆ and R ₇ are -CH ₂ - or -CH = or -CH-, wherein Ί ^R 10 R10 is as defined above; obsession 1 is an integer from 0 to 5, with the proviso that at least two of R ₁ , R ₂ and R 3 are Rq Rg Rg Rg III I -CH-COOH, -CH-PO₃H₂, -CH-COO or -CH-PO3 a group of the general formula wherein R8 is as defined above; wherein Αχ, R ₂ , R 4, R 5, R 8, R 8, ^R 10 / ^R 11 ^{and R} 2 may be different from Αχ, R 2, R 4, R 5, Rq, R 8, ^R 10 ' ^R 11 or R 2, if 1, m, n and q are other than O, or when several of the above groups are present, and salts of these compounds with inorganic or organic bases or basic amino acids. 3. Ligands according to claim 1 or 2, wherein X is thienyl, dihydrothienyl, tetrahydrothienyl, furyl, dihydrofuryl, tetrahydrofuryl, pyranyl. , dihydropyranyl, tetrahydropyranyl, pyrrolyl, 2H-pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, furazanyl, pyrrolidinyl, 2-pyrrolinyl, imidazolinyl, 2-imidazolinyl, pyrazolidinyl, 3-pyrazolinyl, piperidinyl, piperazinyl, morpholinyl, pyranyl, pyranyl, tetrazoyl, dioxanyl, dioxolanyl, benzofuryl, iso (benzofuryl), chromenyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolinyl, phthalazinyl, quinazolinyl , pteridinyl, isochromanyl, indolinyl or isoindolinyl, which may be optionally mono- or polysubstituted, wherein the substituent may be hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched, C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl, straight or branched C 1-6 alkoxy, linear or branched; branched, C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched (C 1 -C 6) hydroxyalkoxy (C 1 -C 6) alkyl, or straight or branched (C 1 -C 6) alkyl polyhydroxyalkoxy (C1-C6) alkyl. 4. Ligands according to claim 2, wherein X is pyrrolidinyl, imidazolyl, oxazolyl, pyrrolyl, pyridyl, pyranyl, tetrahydropyranyl, furyl, dihydrofuryl, tetrahydrofuryl, dioxanyl -, oxazinyl, thienyl, morpholinyl, piperidinyl or dioxolanyl, in which the nitrogen atom is optionally substituted with C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, linear or branched, or a linear or branched C 1-6 alkoxy group, and wherein the carbon atom of the heterocyclic ring is optionally hydroxyl, mercapto, C 1-6 alkyl and / or 1-6 hydroxyalkyl; may be mono- or polysubstituted. The ligands of formula (I) according to claim 1, wherein Z is thiophenediyl, dihydrothiophenediyl, tetrahydrothiophenediyl, furandiyl, dihydrofuranediyl, tetrahydrofuranediyl, pyranediyl, dihydropyranediyl -, tetrahydropyranediyl, pyrroleyl, 2H-pyrroleyl, dihydro-pyrroleyl, tetrahydro-pyrroleyl, imidazolyl, pyrazoldyl, pyridinediyl, 3-hydroxy-6-methyl-2-pyridinediyl, pyrazinyl, pyrimidinediyl, pyrazindiyl, thiazolyldilyl, isothiazolyldilyl, oxazoldyl, isoxazoldyl, furazanediyl, pyrrolidinediyl, 2-pyrrolindilyl, imidazolindyl, 2-imidazolyldilyl, pyrazolidinedyl, 3-pyrazolindyl, - 54 diphenyl, piperazindiyl, morpholindiyl, pyranediyl, tetrahydropyranediyl, tetrazolediyl, dioxanediyl, dioxolanediyl, benzofuranediyl, iso (benzofuranediyl), chromenediyl, indolizindyl, purindil -, quinolinedyl, phthalazindilyl, quinazolindyl, pteridindilyl, isochromanediyl, indoldyl, isoindoldyl, indazoldyl, indolindyl or isoindolindyl, which may be optionally mono- or polysubstituted, where the substituent may be hydroxy, mercapto , straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl, straight or branched C 1-6 polyhydroxyalkyl, straight or branched C 1-6 alkoxy, straight or branched C 1 -C 6 alkoxy (C 1 -C 6) alkyl, straight or branched C 1 -C 6 hydroxyalkoxy (C 1 -C 6) alkyl, or straight or branched chain . C 1-6 polyhydroxyalkoxy (C 1-6) alkyl. The ligands of claim 1, wherein the macromolecule functional group is: Z \ -CH ₂ -CH = CH _2, -CH ₂ -O- (CH _{2) 4} SH, _-CH2 -O- _{(CH2) 2 3} -NHNH-, p II -ch ₂ -o-ch ₂ -c-nh-nh ₂ , -ch ₂ -o-ch ₂ -ch ₂ -nh ₂ , O 0 -ch ₂ -o-ch ₂ -c-nh- (CH ₂ ) ₁₀ -c-nh-nh ₂ , Ο II -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₃ NH-C-CH-CH ₃ , -CH 2 -C ₅ H ₄ -O (CH ₂ ) ₅ CO ₂ CH ₂ C ₆ H 5, ch ₂ -ch ₂ -c ₆ h ₄ -o-ch ₂ -co ₂ -ch ₂ c ₆ h ₅ , -ch ₂ -c ₆ h ₄ -0 (ch ₂ ) ₅ conhnh ₂ , o II -CH ₂ -C ₆ H ₄ -CONHNH-C-CH-CH ₃ , -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₄ sh, ch ₂ -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₃ NHNH ₂ , -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₃ Br, -CH ₂ -C ₆ H ₄ -O (CH ₂ ) ₅ CONHNH- (CH ₂ ) ₃ -NHNH ₂ , -CH ₂ -sh, -CH ₂ -NHN ₂ , - (CH ₂ ) ₃ SH, -CH ₂ -C ₆ H ₄ -O-CH ₂ -COBt, -C ₆ H ₄ NHCOCH ₂ Br, o II -ch ₂ -c ₆ h ₄ -och ₂ -c-nh- (ch ₂ ) ₂ nh _{2 /} -ch ₂ -c ₆ h ₄ -nh ₂ , -c ₆ h ₄ ~ n ₂ , -c ₆ h ₄ ncs, -nhco-nh-nh ₂ , -ncs-nh-nh ₂ , O 0 0 / \ II II -ch ₂ -c ₆ h ₄ -o-ch ₂ -ch-ch ₂ , -ch ₂ -c ₆ h ₄ -o-ch ₂ -C-NH (CH ₂ ) ₁₀ -c-n hn ₂ , 0 II -CH ₂ -C ₆ H ₄ -O-CH ₂ -CHOH-CH ₂ -NH (CH ₂ ) ₁₀ -C-NHNH ₂ , O CH ₃ -OCH ₂ -CN-CH ₂ - (CHOH) ₄ -CH ₂ OH, (c), (cl), (c2), (d) or (dl). The ligands of claim 1, wherein W is (d2), (e), (el), (e2), (e3), (e4), (f), (fi), (g), (gl). ), (h), (h1), (h2), (h3), (i), (j) or (k). 8. Ligands of formula (II) wherein R 1, R ₂ , R ₃ and W are as defined in claim 1 for formula (I), and • ο - 56 R'1, R * 2 and '' β are each independently hydrogen, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl or polyhydroxyalkyl; a functional group which allows the attachment of the macrocycle of formula I to a macromolecule; linear or branched C 1-6 alkoxy (C 1-6) alkyl, straight or branched hydroxy (C 1-6) alkoxy (C 1-6) alkyl, or straight or branched polyhydroxy; - (C 1 -C 6) alkoxy (C 1 -C 6) alkyl, aryl or mono- or polysubstituted aryl, wherein the substituents are independently halogen, hydroxy, nitro or (C 1 -C 6) alkyl, (C 1 -C 6) hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy or C 1-6 alkoxy (C 1-6) alkyl, aralkyl or mono- or polysubstituted aralkyl, wherein the substituents independently selected from the group consisting of halogen, hydroxy, nitro and C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 polyhydroxyalkyl, C 1-6 alkoxy, or C 1-6 alkoxy (C 1-6) alkyl, wherein the alkyl groups of the aralkyl are C 1-6 straight or branched chain alkyl- • ♦ ♦ · · · «• · · 4 - 57 may be provided with the proviso that at least two of R 1, R ₂ or R ₃ are Rg Rg Rg Rg -CH-COOH, -CH-PO ₃ H ₂ , -CH-COO or -ch-p ₃ - wherein Rg is as defined in claim 1 and salts of these ligands with organic or inorganic bases or basic amino acids. 9. Ligands of formula (III) wherein R ₂ and R ₃ is hydrogen, methyl or ethyl, and W is as defined in claim 5. The ligands of formula (III) according to claim 9, wherein R ₂ is hydrogen and R "is _3, and W is (d2), (e), (el), (e2), (e3), (e4), (f), (fi), (g), (gl), (h), (hl), (h2), (h3), (i), (j) or (k). 11. Ligand of formula (Ia). The ligand of formula (III) according to claim 9, wherein R ₂ and R ₃ is methyl, and W is a group of formula (e). 13. A ligand of formula (1m). 14. Ligand of formula (Irish). 15. A ligand of formula (Is). 16. A ligand of formula (If). 17. Process for the preparation of compounds of formula I The substituent wherein the substituents have the meaning given in claim 2, characterized in that a) a compound of formula IV W - NH ₂ (IV) wherein W is as defined in claim 2 with a compound of formula (V) P- (CH) _m - (CH) _n -CH-NH-Ts III io m ^{r r r} 4 5 wherein R4, _R5 and Rio is, m and n is the first Claim 1, P represents a leaving group which may be mesyloxy or tosyloxy or bromo, chloro or iodo; and Ts is a tosyl group, b) reacting the resulting compound of formula VII with a compound of formula VIII wherein: 1 is as defined in claim 2, c) removing the tosyl group from the resulting compound of formula IX; and d) alkylating the resulting compound. A process for the preparation of a compound of formula (I) according to claim 1, wherein W is a group of formula (a2) wherein p and q are as well as R 1, R ₂ , R 3, R ₃ , R 12 * ^A 1r ^A 2 ' Αβ, A4 and Z are as defined in claim 1, characterized in that a) a compound of formula IVa H ₂ N-W'-NH ₂ (IVa) - wherein W 'is a group of formula (a3) wherein p and q and R ₁ and R ₂ are as defined in claim 1, and X · is a group of formula (11), (12), (13) or (14), and R8 and R7, taken together with the carbon atom to which they are attached, optionally form a heterocyclic ring of up to 12 membered two fused rings wherein 1-4 membered heteroatoms, such as oxygen, -N = and / or N-R8, wherein R ₈ is as defined in claim 1, the heterocyclic ring being optionally substituted one or more times, wherein the substituents are hydroxy, mercapto, straight or branched C 1-6 alkyl, straight or branched C 1-6 hydroxyalkyl a linear or branched C 1-6 polyhydroxyalkyl, a straight or branched C 1-6 alkoxy (C 1-6) alkyl, a linear or branched C 1-6 hydroxy- alkoxy (C 1-6) alkyl, straight or branched (C 1-6) polyhydroxyalkoxy (C 1-6) alkyl, or functional groups that allow they link the heterocyclic ring to a macromolecule, provided that when p and q are 0, then R'g and R * 7 are -CH ₂ - or -CH = or -CH- generally ^R 10 where: Rio is a compound of formula (V) according to claim 17, as defined in claim 1, b) the resulting compound of formula (VIIa) is treated with one With a compound of formula VIII according to claim 17, c) removing the tosyl groups from the resulting compound of formula IXa; and d) alkylating the resulting compound. 19. A process for the preparation of compounds of formula II according to claim 8, characterized in that: a) a compound of formula IV W - NH ₂ (IV) - wherein W is as defined in claim 8 - reacting with a compound of formula (X) wherein: R ' ₂ has the meaning given in claim 8, and P 'is tosyl, mesyl, phenylsulfonyl or 44 · - 61-methoxyphenylsulfonyl, b) reacting the resulting compound of formula XI with a compound of formula XII, wherein R * 3 is as defined in claim 8 and P 'has the meaning given above, c) reacting the resultant compound of formula XIII with a compound of formula XIV, wherein P 'has the meaning given above and R 1 is as defined in claim 8, d) from the resultant compound of formula XV: a The P 'group is removed and e) alkylating the resulting compound. 1 ------ 2-O-.- Somlogec-ionic complexes containing one or more metals, formed by at least one ligand of formula (I) according to claim 1 with at least one metal ion such as lanthanide ion salts of metal ions, barium, bismuth, lead and / or ⁹⁹ⁱⁿ Tc, ⁹⁰ Y, ⁶⁴ Cu and / or ⁶⁹ Yb radioisotopes and pharmaceutically acceptable inorganic salts of organic complexes or basic amino acids. Complexes containing one or two metals according to claim 20, characterized in that they contain as gad ion Lznium, europium, dysprosium, iron (III) ion, manganese (II) ion and / or barium. Diagnostic composition 22, characterized in that it contains at least one complex according to claim 20 or 21. ------- 2-3 -.— Diagnostic Code —azzal — j ο- 1 -1 e • 4 · Φ · · · · · · · · · · · · · e - e - ve, - that the leg leg ¹ - ---- '~ ^Λ -' --- - contains a complex for kula or polymer 24. The composition of claim 22 or 23, wherein the composition comprises a solution of the complex in an aqueous solvent. 25. A human therapeutic composition having a sign 1, comprising at least one complex as defined in any one of claims 1-16. A ligand according to any one of claims 1 to 4, formed by metal, which may be ^99m Tc, Hhn, ⁹⁰ Y, ²¹² Bi, 169 _Yb or ⁶⁴ CuXahol linked to a molecular molecule or polymer or liposome in the complex living organism.